NCT00793572View on ClinicalTrials.gov

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Refractory Plasma Cell Myeloma
Interventions
PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo transplantation

DRUG

Bortezomib

Given SC

DRUG

Cyclosporine

Given IV

DRUG

Cyclosporine

Given PO

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan

Given IV

DRUG

Mycophenolate Mofetil

Given PO

PROCEDURE

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Undergo transplantation

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo transplantation

PROCEDURE

Syngeneic Bone Marrow Transplantation

Undergo transplantation

RADIATION

Total-Body Irradiation

Undergo radiotherapy

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00793572 - Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter